Phosphorylation of tyrosine residues is an important mode of cellular regulation of enzyme activities and proteinprotein interactions.
1
H-NMR spectrum. The arylidene rhodanine (H) was subsequently treated with a variety of arylamines (G1-18) to obtain ITZ1-18. 13 Commercially available amines (G1-5) were purchased, while others (G6-18) were prepared stating from 3-or 4-nitrophenol as shown in Scheme 1.
Compounds ITZ1-18 were evaluated for their inhibitory activity against PTP1B. To determine the half-maximal inhibitory concentrations (IC 50 ), p-nitrophenyl phosphate (pNPP) hydrolase activity of PTP1B was measured in the presence of an inhibitor at a series of different concentrations. The IC 50 values for the ITZ compounds are summarized in Table 1 . Six of the compounds (ITZ9-10 and ITZ14-17) exhibited IC 50 values in low micromolar concentration ranges. ITZ15 was the most potent with an IC 50 of 1.4 μM. Kinetic analysis of the inhibitory action of ITZ15, using a Lineweaver-Burk plot, demonstrated that ITZ15 was a competitive inhibitor of PTP1B ( Figure 1) .
To obtain the selectivity profile of ITZ15, the inhibitory activity was determined against the human PTPs, T cell protein tyrosine phosphatase (TCPTP) and Src homology-2 domain-containing protein tyrosine phosphatase-1 (SHP1), and Vaccinia H1-related (VHR) phosphatase, and a yeast PTP, YPTP1. ITZ15 showed 17-fold selectivity over TCPTP, which is most homologous to PTP1B, and showed 4 ~ 34-fold selectivity over other phosphatases examined in this experiment.
ITZ15 was evaluated for its in vivo efficacy as an antiobesity and hypoglycemic agent. Five week-old mice susceptible to diet-induced obesity/diabetes (C57BL/6J Jms Slc male) were fed a high-fat diet (HFD) ad libitum for 8 weeks, followed by a HFD + ITZ15 for 4 weeks. ITZ15 was provided with the diet (1.0 g of ITZ15/kg of diet). The daily uptake of ITZ15 was approximately 2.8 mg/day/mouse, equivalent to 78 mg/day/kg of mouse weight. Two other groups of mice were fed a low-fat diet (LFD) or HFD, throughout the 12-week study period, as lean and obese controls. In this experiment, no significant differences in body weight and glucose tolerance were observed between the drug-fed and obese control groups (data not shown). Given that ITZ15 is a potent inhibitor of PTP1B in vitro, the absence of an in vivo effect might be due to low bioavailability. As a factor affecting absorption, distribution, metabolism, and excretion (ADME) properties, the logD value of ITZ15 at pH 7.5 was predicted to be 2.69, which resides in the upper range of typical drugs under clinical use. Improvement of the ADME properties of ITZ15 will require the study of additional properties of the compound such as its solubility, serum protein binging, and metabolic stability.
In summary, we synthesized a series of thiazolidinone derivatives and evaluated the inhibitory activity against PTP1B. Most of the compounds behaved as inhibitors of PTP1B, with the lowest IC 50 of 1.4 μM observed with ITZ15. In contrast to the in vitro efficacy of ITZ15 as a potent 422 g, 11 mmol) , and methyl iodide (1.6 g, 11 mmol) in ethanol (30 mL) was stirred at room temperature (RT). for 4 h. Aqueous workup followed by column chromatography afforded compound B (0.87 g, 59% yield).
4-Ethoxycarbonylmethyloxy-3-methoxybenzaldehyde (D). To a mixture of vanillin (0.152 g, 1 mmol) and anhydrous K 2 CO 3 (0.207 g, 1.5 mmol) in dry acetone (6 mL) was added ethyl α-bromoacetate (0.251 g, 1.5 mmol) at RT. The mixture was heated to reflux for 4 h. Aqueous workup provided D (0.225 g, 94% yield) pure enough to be used for the next reaction without further purification.
General Procedure for the Synthesis of F6-18. A mixture Figure 1 . Lineweaver-Burk analysis for PTP1B catalyzed reactions in the presence of ITZ15 at the concentrations specified in the inset. of m-or p-nitrophenol (2.0 mmol), K 2 CO 3 (10 mmol), and derivatives of benzyl chloride or benzyl bromide (2.2 mmol) in dry DMF (4 mL) were heated at 65-70 ºC for 1-2 h. After aqueous workup, the crude product was purified by column chromatography.
General Procedure for G6-18. To a solution of F6-18 (0.10 mmol) in 50% aqueous MeOH (25 mL) was added concentrated HCl (1.0 mL). Zinc powder (2.0 mmol) was then added with vigorous stirring. Additional concentrated HCl (2.0 mL) was added dropwise and the reaction was continued at RT for 30 min. Aqueous workup afforded G6-18 in an essentially pure form in > 80% yield.
Compound H. A solution of B (1.50 g, 10 mmol) and D (2.38 g, 10 mmol) in 2-propanol (15 mL) was heated to 65-70°C for 3 h. After aqueous workup, the residue was purified by recrystallization or column chromatography (1.58 g, 43% yield).
General Procedure for the Ethyl Esters of ITZ1-18 (I1-18). A solution of H (0.10 mmol) and G1-18 (0.10 mmol) in ethanol (4.0 mL) was heated to reflux for 6 h. After evaporation of the solvent, the resulting solid was purified by column chromatography.
General Procedure for ITZ1-18. A solution of I1-18 (0.052 mmol) in THF (1 mL) and 2 M aqueous NaOH (0.030 mL) was heated to reflux for 1.5 h. The reaction mixture was acidified by addition of 1 M HCl and THF was evaporated. The resulting solids were washed with H 2 O and dried under high vacuum to be used as inhibitors without further purification.
PTP1B Assay. The enzyme activity of PTP1B and other PTPs was determined as described previously.
14,15 PTP1B was diluted before the experiment to 400 nM in enzyme dilution buffer (25 mM Hepes, 5.0 mM EDTA, 1.0 mM DTT, 1.0 mg/mL bovine serum albumin, pH 7.3). For a 50 μL reaction, 5.0 μL of inhibitor solution in DMSO was added to a mixture containing 5.0 μL enzyme, 10 μL buffer (250 mM Hepes, 25 mM EDTA, pH 7.0), and water (25 μL). After a 10 min preincubation period at 37 °C, 5.0 μL of pNPP solution (20 mM) was added and the reaction proceeded for 3 min at 37 °C. The reaction was then stopped by the addition of 0.5 M NaOH solution (0.95 mL) and the absorbance of the mixture at 405 nm was measured with a spectrophotometer. For the Lineweaver-Burk plot analysis, the enzyme reaction was started by addition of PTP1B to a buffer solution containing pNPP and inhibitor.
